During a live event, Brittany Siontis, MD, a sarcoma oncologist at Mayo Clinic, and participants examined how to choose between the systemic options for progressive desmoid tumors ...

Peter Voorhees, MD, of Atrium Health Levine Cancer Institute, discusses data from the MonumenTAL-3 study (NCT05455320), a ...

CMS proposes deeper 340B drug payment cuts for hospitals, reshaping outpatient cancer economics, consolidation incentives, and patient cost-sharing. The Centers for Medicare & Medicaid Services (CMS) ...

FDA concurrence supports US launch of a 2:1 randomized ~490-patient phase 3 comparing TLX591-Tx plus SOC versus SOC in ...

During a live event, Andrew Brunner, MD, and participants discussed second-line therapy selection in lower-risk MDS following ESA failure. After the failure of frontline erythropoiesis-stimulating ...

The T-cell immunotherapy Orca-T has gained FDA approval in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) ...

NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...

Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims ...

Lupin’s ANDA received tentative FDA approval for four enzalutamide tablet strengths, with final approval deferred until ...

Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL ...

A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...

Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors. In an interview with Targeted Oncology at the ...